Exploring height outcomes with adjuvant aromatase inhibition in growth hormone–deficient male survivors of childhood cancer
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Netanya I Pollock und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Cancer Survivors, Body Height, Human Growth Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Aromatase inhibitors (AI) may improve height in short stature conditions; however, the effect in childhood cancer survivors (CCS) is unknown. We assessed final adult height (FAH) in CCS treated with AI and GH compared with those treated with GH alone.
Methods
Retrospective cohort study of GH‐deficient male CCS treated between 2007 and 2023. FAH was noted as the height at the fusion of growth plates or 18 years of age. Multivariable linear regression was used to examine treatment association with FAH, adjusting for other risk factors.
Results
Ninety‐two patients were included; 70 were treated with GH and 22 with combination AI/GH. The mean age at GH initiation did not differ between groups. The mean age at AI initiation was 13.7 ± 1.9 years. A greater proportion of patients in the AI/GH group were treated with stem cell transplantation, abdominal radiation, total body irradiation, and cis ‐retinoic acid ( p < .01). Multivariable linear regression demonstrated no significant treatment association with FAH Z‐score (β = 0.04, 95% CI: −0.9 to 0.9). History of spinal radiation (β = −0.93, 95% CI: −1.7 to −0.2), lower starting height Z‐score (β = −0.8, 95% CI: −1.2 to −0.4), and greater difference between bone age and chronological age (β = −0.3, 95% CI: −0.5 to −0.07) were associated with lower FAH Z‐score.
Conclusions
Adjuvant AI was not associated with increased FAH in male CCS compared with GH monotherapy. Future work is needed to determine the optimal adjunctive treatment to maximize FAH for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Nephrology, Stanford Children's Health, Stanford, California, USA.
- Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Paediatrics and Child Health, University College Cork, Cork, Ireland.
- INFANT Research Centre, University College Cork, Cork, Ireland.
ORCID-Profile: Netanya I Pollock, Minkeun Song, Yimei Li, Colin P Hawkes, Sogol Mostoufi-Moab
Förderung
- NIDDK NIH HHS
Zitieren
APA
Pollock, N. I., Song, M., Wolf, A. J., Li, Y., Hawkes, C. P., Motamedi, N., Denburg, M. R., & Mostoufi-Moab, S. (2024). Exploring height outcomes with adjuvant aromatase inhibition in growth hormone–deficient male survivors of childhood cancer. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31117
Vancouver
Pollock NI, Song M, Wolf AJ, Li Y, Hawkes CP, Motamedi N, et al. Exploring height outcomes with adjuvant aromatase inhibition in growth hormone–deficient male survivors of childhood cancer. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31117
BibTeX
@article{Pollock2024,
author = {Pollock, Netanya I and Song, Minkeun and Wolf, Alexander J and Li, Yimei and Hawkes, Colin P and Motamedi, Niloofaralsadat and Denburg, Michelle R and Mostoufi-Moab, Sogol},
title = {Exploring height outcomes with adjuvant aromatase inhibition in growth hormone–deficient male survivors of childhood cancer},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31117}
}
EUVIMED